Buy signal, second week
Pfizer stock climbs 4.8% as the buy signal's confirmation week closes higher
Our view last week
Pfizer stock's confirmation week on the buy signal closes almost flat, +0.1%, after last week's 7% bounce. Under the surface the picture stays buyer-led: nearly three-quarters of the last session's volume came in on the buy side, and the weekly MACD has just crossed bullish. This technical analysis shows a stock that hasn't yet attacked its recent highs, with healthcare stocks in a strength phase behind it.
This week's summary
Pfizer stock closed the week up 4.8%, its second gain since the buy signal fired: the weekly structure stays bullish, above the 50-week average and with the ADX climbing, but two warning signs are creeping into the volume picture. This technical analysis shows three rising daily lows toward the 26 area, and a stock still far from its all-time high, though the nearest resistance — the 30-week high — sits just 2.4% away.
IQS Phase
62
ordinary
Signal Strength
38
medium · weak
Sizing
REDUCED
Ranking
#110 / 167
US stocks in progress
Trade P&L %
+4.90%
from signal to date, no stop loss
Rank position
ranks 110th among the 167 Longs already running for US stocks in our ranking, with a signal strength of 38 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein strong phase
Performanceweekly +4.33% · monthly +9.53%
PFE belongs to the health care sector (reference ETF XLV). The sector is classified in strong phase according to our weekly reading.
restricted Platinum content